肝癌术后早期应用胸腺肽α 1对T淋巴细胞亚群的影响

目的：探讨肝癌患者术后早期应用胸腺肽α1对T淋巴细胞亚群的影响。方法： 46例肝癌手术患者, 随机分治疗组（23例）和对照组（23例）, 治疗组于术后1、3、5 d皮下注射胸腺肽α1 1.6 mg，观察2组术前后第1、4、7 d CD3+、CD4+、CD8+、CD4+/CD8+的变化情况。结果：（1）组内比较：对照组术后CD4+、CD4+/CD8+低于术前（P<0.05），术后第1、4、7 d CD8+高于手术前（P<0.05）。治疗组CD3+、CD4+、 CD4+/CD8+术后与术前相比无显著差异；CD3+、CD4+/CD8+术后第1、7 d比较有显著差异（P<0.05）。（2）组间比较：CD4+、CD4+/CD8+治疗组高于对照组（术后第1、4、7 d均P<0.05），治疗组CD8+细胞百分率低于对照组（术后第1、4、7 d均P<0.05）；治疗组CD3+细胞百分率高于对照组（术后第4、7 d P<0.05）。结论： 手术对肝癌患者术后T淋巴细胞免疫功能有抑制作用，胸腺肽α1对T淋巴细胞免疫功能有调节作用。

Effects of early application of thymosin peptide alpha 1 on T lymphocyte subsets after hepatectomy in patients with hepatocellular carcinoma

AIM: To investigate the effects of early application of thymosin peptide alpha 1 on lymphocyte subsets after operation in patients with hepatocellular carcinoma. METHODS: Forty-six patients with hepatocellular carcinoma were randomly divided into control and treatment groups for this study. Thymosin α1 at dose of 1.6 mg was injected subcutaneously on day 1, 3, and 5 after operation in treatment group. The percentages of CD3+, CD4+ and CD8+ cells, and CD4+/CD8+ ratio in both groups were counted before operation and on day 1, 4, and 7 after hepatectomy. RESULTS: CD4+ cell population and CD4+/CD8+ ratio decreased, but CD8+ increased after operation in control group (P<0 05). In thymosin peptide alpha 1 treatment group, there was no statistical difference in the percentages of CD3+, CD4+, CD8+, and CD4+/CD8+ before and after operation. In addition, thymosin α1 significantly increased CD4+ cell population and CD4+/CD8+ ratio (P<0 05). CONCLUSION: Operation suppresses the immune function in patients with hepatocellular carcinoma. Thymosin α1 increases CD4+ T lymphocyte subsets in patients after operation.